Trial Profile
A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC in Clinical Practice to Characterize Risk of Herpetic Infection Among Patients, Close Contacts, Health Care Providers & Long-term Safety in Treated Patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Amgen
- 03 Apr 2023 Planned number of patients changed from 920 to 300.
- 01 Mar 2023 Planned End Date changed from 31 Aug 2032 to 31 Aug 2037.
- 01 Mar 2023 Planned primary completion date changed from 31 Aug 2032 to 31 Aug 2037.